drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00334 | DB01001 | 867 | 688 | [
"DDInter1326",
"DDInter1632"
] | Olanzapine | Salbutamol | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
867,
24,
688
]
],
[
[
867,
24,
874
],
[
874,
24,
688
]
],
[
[
867,
24,
1148
],
[
1148,
63,
688
]
],
[
[
867,
6,
8374
],
[
8374,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Is... |
DB01227 | DB12500 | 1,301 | 283 | [
"DDInter1043",
"DDInter714"
] | Levacetylmethadol | Fedratinib | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1301,
25,
283
]
],
[
[
1301,
25,
351
],
[
351,
23,
283
]
],
[
[
1301,
64,
1419
],
[
1419,
24,
283
]
],
[
[
1301,
24,
951
],
[
951,
... | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib"... | Levacetylmethadol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Levacetylmethadol may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moder... |
DB00352 | DB08904 | 482 | 375 | [
"DDInter1814",
"DDInter342"
] | Tioguanine | Certolizumab pegol | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
482,
25,
375
]
],
[
[
482,
63,
1461
],
[
1461,
23,
375
]
],
[
[
482,
24,
231
],
[
231,
24,
375
]
],
[
[
482,
24,
200
],
[
200,
6... | [
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vit... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Sta... |
DB11057 | DB12141 | 720 | 971 | [
"DDInter1223",
"DDInter817"
] | Mineral oil | Gilteritinib | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
720,
24,
971
]
],
[
[
720,
63,
485
],
[
485,
24,
971
]
],
[
[
720,
24,
730
],
[
730,
63,
971
]
],
[
[
720,
24,
1297
],
[
1297,
2... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazin... |
DB11901 | DB12010 | 913 | 214 | [
"DDInter107",
"DDInter785"
] | Apalutamide | Fostamatinib | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resi... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
913,
25,
214
]
],
[
[
913,
64,
976
],
[
976,
24,
214
]
],
[
[
913,
25,
861
],
[
861,
63,
214
]
],
[
[
913,
63,
51
],
[
51,
24,
... | [
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
... | Apalutamide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Apalutamide may lead to a major life threatening interaction when taken with Ripretinib and Ripretinib may cause a moderat... |
DB00314 | DB01362 | 894 | 497 | [
"DDInter288",
"DDInter960"
] | Capreomycin | Iohexol | Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
894,
25,
497
]
],
[
[
894,
25,
258
],
[
258,
40,
497
]
],
[
[
894,
21,
28681
],
[
28681,
60,
497
]
],
[
[
894,
24,
891
],
[
891,
... | [
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} (Com... | Capreomycin may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Capreomycin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Capreomycin may cause a moderate interaction that c... |
DB00370 | DB00748 | 1,251 | 662 | [
"DDInter1230",
"DDInter297"
] | Mirtazapine | Carbinoxamine | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
1251,
24,
662
]
],
[
[
1251,
24,
28
],
[
28,
40,
662
]
],
[
[
1251,
63,
1594
],
[
1594,
24,
662
]
],
[
[
1251,
24,
128
],
[
128,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that co... |
DB00214 | DB06292 | 1,028 | 549 | [
"DDInter1836",
"DDInter474"
] | Torasemide | Dapagliflozin | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1028,
24,
549
]
],
[
[
1028,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1028,
6,
6017
],
[
6017,
45,
549
]
],
[
[
1028,
21,
28898
],
[
28898... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Torasemide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dapagliflozin (Compound)
Torasemide (Compound) causes Constipation (Side Effect... |
DB09263 | DB09322 | 1,436 | 1,114 | [
"DDInter1399",
"DDInter1966"
] | Patiromer | Zinc sulfate | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Moderate | 1 | [
[
[
1436,
24,
1114
]
],
[
[
1436,
63,
251
],
[
251,
23,
1114
]
],
[
[
1436,
24,
1019
],
[
1019,
62,
1114
]
],
[
[
1436,
63,
251
],
[
251,
... | [
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[... | Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and D... |
DB01041 | DB01142 | 770 | 1,264 | [
"DDInter1789",
"DDInter593"
] | Thalidomide | Doxepin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
770,
24,
1264
]
],
[
[
770,
63,
508
],
[
508,
24,
1264
]
],
[
[
770,
24,
401
],
[
401,
24,
1264
]
],
[
[
770,
24,
649
],
[
649,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prometh... |
DB00439 | DB11718 | 289 | 927 | [
"DDInter341",
"DDInter640"
] | Cerivastatin | Encorafenib | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
289,
24,
927
]
],
[
[
289,
24,
112
],
[
112,
23,
927
]
],
[
[
289,
24,
372
],
[
372,
24,
927
]
],
[
[
289,
24,
484
],
[
484,
63,... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine ... |
DB06663 | DB09020 | 1,154 | 28 | [
"DDInter1398",
"DDInter212"
] | Pasireotide | Bisacodyl | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1154,
24,
28
]
],
[
[
1154,
21,
28809
],
[
28809,
60,
28
]
],
[
[
1154,
64,
739
],
[
739,
24,
28
]
],
[
[
1154,
25,
938
],
[
938,
... | [
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Pasireotide",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is cau... | Pasireotide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Pasireotide may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Pasireo... |
DB00959 | DB01135 | 1,486 | 648 | [
"DDInter1191",
"DDInter590"
] | Methylprednisolone | Doxacurium | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. | Moderate | 1 | [
[
[
1486,
24,
648
]
],
[
[
1486,
24,
1319
],
[
1319,
40,
648
]
],
[
[
1486,
40,
251
],
[
251,
24,
648
]
],
[
[
1486,
40,
1220
],
[
1220,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxacurium"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mivacurium"... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Mivacurium and Mivacurium (Compound) resembles Doxacurium (Compound)
Methylprednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when ... |
DB00969 | DB08880 | 2 | 1,510 | [
"DDInter52",
"DDInter1771"
] | Alosetron | Teriflunomide | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
2,
24,
1510
]
],
[
[
2,
24,
129
],
[
129,
63,
1510
]
],
[
[
2,
63,
1684
],
[
1684,
24,
1510
]
],
[
[
2,
63,
1622
],
[
1622,
25,
... | [
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[... | Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caf... |
DB00366 | DB00899 | 1,594 | 411 | [
"DDInter600",
"DDInter1579"
] | Doxylamine | Remifentanil | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Moderate | 1 | [
[
[
1594,
24,
411
]
],
[
[
1594,
24,
1322
],
[
1322,
40,
411
]
],
[
[
1594,
24,
704
],
[
704,
1,
411
]
],
[
[
1594,
21,
29231
],
[
29231,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Remifentanil (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Remifentanil (Compound)
... |
DB00446 | DB09473 | 597 | 884 | [
"DDInter351",
"DDInter918"
] | Chloramphenicol | Indium In-111 oxyquinoline | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
597,
24,
884
]
],
[
[
597,
24,
112
],
[
112,
24,
884
]
],
[
[
597,
24,
148
],
[
148,
63,
884
]
],
[
[
597,
63,
10
],
[
10,
24,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"M... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when ... |
DB05773 | DB09122 | 1,047 | 1,613 | [
"DDInter1848",
"DDInter1409"
] | Trastuzumab emtansine | Peginterferon beta-1a | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1047,
24,
1613
]
],
[
[
1047,
63,
671
],
[
671,
24,
1613
]
],
[
[
1047,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1047,
24,
1155
],
[
1155... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases wh... |
DB00005 | DB08895 | 1,057 | 976 | [
"DDInter687",
"DDInter1825"
] | Etanercept | Tofacitinib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1057,
25,
976
]
],
[
[
1057,
23,
1193
],
[
1193,
62,
976
]
],
[
[
1057,
23,
1461
],
[
1461,
23,
976
]
],
[
[
1057,
24,
200
],
[
200,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Etanercept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vita... |
DB00382 | DB00631 | 62 | 372 | [
"DDInter1734",
"DDInter405"
] | Tacrine | Clofarabine | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
62,
24,
372
]
],
[
[
62,
24,
927
],
[
927,
63,
372
]
],
[
[
62,
63,
1560
],
[
1560,
24,
372
]
],
[
[
62,
24,
663
],
[
663,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspa... |
DB00054 | DB14357 | 1,432 | 944 | [
"DDInter6",
"DDInter347"
] | Abciximab | Chamomile | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
1432,
23,
944
]
],
[
[
1432,
25,
256
],
[
256,
23,
944
]
],
[
[
1432,
64,
582
],
[
582,
23,
944
]
],
[
[
1432,
24,
1061
],
[
1061,
... | [
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
... | Abciximab may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Abciximab may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a minor interaction that... |
DB00373 | DB12500 | 461 | 283 | [
"DDInter1809",
"DDInter714"
] | Timolol | Fedratinib | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
461,
24,
283
]
],
[
[
461,
24,
1593
],
[
1593,
23,
283
]
],
[
[
461,
24,
1419
],
[
1419,
24,
283
]
],
[
[
461,
63,
1010
],
[
1010,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"C... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cau... |
DB00060 | DB00307 | 912 | 1,101 | [
"DDInter947",
"DDInter202"
] | Interferon beta-1a | Bexarotene | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Moderate | 1 | [
[
[
912,
24,
1101
]
],
[
[
912,
24,
609
],
[
609,
62,
1101
]
],
[
[
912,
24,
362
],
[
362,
23,
1101
]
],
[
[
912,
24,
287
],
[
287,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromy... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00072 | DB01097 | 550 | 1,377 | [
"DDInter1846",
"DDInter1033"
] | Trastuzumab | Leflunomide | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
550,
25,
1377
]
],
[
[
550,
24,
949
],
[
949,
63,
1377
]
],
[
[
550,
24,
126
],
[
126,
24,
1377
]
],
[
[
550,
24,
66
],
[
66,
25... | [
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (form... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Trastuzuma... |
DB01037 | DB01364 | 1,161 | 22 | [
"DDInter1653",
"DDInter650"
] | Selegiline | Ephedrine | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Major | 2 | [
[
[
1161,
36,
22
]
],
[
[
1161,
1,
80
],
[
80,
24,
22
]
],
[
[
1161,
1,
11353
],
[
11353,
40,
22
]
],
[
[
1161,
40,
11246
],
[
11246,
... | [
[
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
]
],
[
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Amphetamine"
],
[
"Amphetamine",
... | Selegiline (Compound) resembles Ephedrine (Compound) and
Selegiline (Compound) resembles Amphetamine (Compound) and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Selegiline (Compound) resembles Benzyl alcohol (Compound) and Benzyl alcohol (Compound) resembles Ephe... |
DB00835 | DB00906 | 100 | 1,567 | [
"DDInter245",
"DDInter1801"
] | Brompheniramine | Tiagabine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Moderate | 1 | [
[
[
100,
24,
1567
]
],
[
[
100,
6,
8374
],
[
8374,
45,
1567
]
],
[
[
100,
63,
530
],
[
530,
24,
1567
]
],
[
[
100,
24,
537
],
[
537,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tiagabine (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Bromphenir... |
DB09389 | DB12130 | 517 | 1,017 | [
"DDInter1315",
"DDInter1094"
] | Norgestrel | Lorlatinib | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
517,
24,
1017
]
],
[
[
517,
64,
1101
],
[
1101,
23,
1017
]
],
[
[
517,
62,
14
],
[
14,
24,
1017
]
],
[
[
517,
63,
549
],
[
549,
... | [
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Norgestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene... | Norgestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Norgestrel may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause ... |
DB01142 | DB01192 | 1,264 | 560 | [
"DDInter593",
"DDInter1372"
] | Doxepin | Oxymorphone | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
1264,
24,
560
]
],
[
[
1264,
63,
828
],
[
828,
1,
560
]
],
[
[
1264,
6,
12523
],
[
12523,
45,
560
]
],
[
[
1264,
21,
28695
],
[
28695,... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"O... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Doxepin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Oxymorphone (Compound)
Doxepin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effe... |
DB00011 | DB06688 | 1,451 | 1,430 | [
"DDInter944",
"DDInter1677"
] | Interferon alfa-n1 | Sipuleucel-T | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1451,
24,
1430
]
],
[
[
1451,
24,
869
],
[
869,
24,
1430
]
],
[
[
1451,
25,
676
],
[
676,
63,
1430
]
],
[
[
1451,
24,
310
],
[
310,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Upadacitinib and Upa... |
DB00470 | DB00647 | 530 | 675 | [
"DDInter601",
"DDInter528"
] | Dronabinol | Dextropropoxyphene | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Major | 2 | [
[
[
530,
25,
675
]
],
[
[
530,
24,
649
],
[
649,
1,
675
]
],
[
[
530,
23,
307
],
[
307,
1,
675
]
],
[
[
530,
25,
1301
],
[
1301,
40,... | [
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Cl... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Dextropropoxyphene (Compound)
Dronabinol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Dextropropoxyphene... |
DB00418 | DB00910 | 536 | 1,041 | [
"DDInter1650",
"DDInter1394"
] | Secobarbital | Paricalcitol | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Moderate | 1 | [
[
[
536,
24,
1041
]
],
[
[
536,
63,
386
],
[
386,
25,
1041
]
],
[
[
536,
24,
1098
],
[
1098,
64,
1041
]
],
[
[
536,
21,
28681
],
[
28681,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol a... |
DB00741 | DB00881 | 167 | 954 | [
"DDInter885",
"DDInter1554"
] | Hydrocortisone | Quinapril | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
167,
24,
954
]
],
[
[
167,
63,
1638
],
[
1638,
1,
954
]
],
[
[
167,
24,
664
],
[
664,
1,
954
]
],
[
[
167,
63,
1523
],
[
1523,
4... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril (Compound) resembles Quinapril... |
DB06317 | DB11817 | 1,626 | 1,259 | [
"DDInter630",
"DDInter165"
] | Elotuzumab | Baricitinib | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1626,
25,
1259
]
],
[
[
1626,
24,
949
],
[
949,
24,
1259
]
],
[
[
1626,
63,
563
],
[
563,
24,
1259
]
],
[
[
1626,
24,
1129
],
[
1129,
... | [
[
[
"Elotuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formal... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Elotuzumab ... |
DB00333 | DB00427 | 576 | 1,233 | [
"DDInter1166",
"DDInter1879"
] | Methadone | Triprolidine | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Moderate | 1 | [
[
[
576,
24,
1233
]
],
[
[
576,
6,
12523
],
[
12523,
45,
1233
]
],
[
[
576,
1,
358
],
[
358,
63,
1233
]
],
[
[
576,
35,
262
],
[
262,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",... | Methadone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Triprolidine (Compound)
Methadone (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Methadone (Compound) resembles Clidinium (Compound) and Meth... |
DB00277 | DB01583 | 1,031 | 624 | [
"DDInter1791",
"DDInter1075"
] | Theophylline | Liotrix | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
1031,
24,
624
]
],
[
[
1031,
24,
1152
],
[
1152,
1,
624
]
],
[
[
1031,
24,
542
],
[
542,
40,
624
]
],
[
[
1031,
6,
3486
],
[
3486,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Co... |
DB00553 | DB01050 | 92 | 848 | [
"DDInter1177",
"DDInter900"
] | Methoxsalen | Ibuprofen | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
92,
24,
848
]
],
[
[
92,
21,
28942
],
[
28942,
60,
848
]
],
[
[
92,
24,
1299
],
[
1299,
24,
848
]
],
[
[
92,
24,
178
],
[
178,
6... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Methoxsalen",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis bullous"
],
[
"Dermatitis bullous",
"{u} (S... | Methoxsalen (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Ibuprofen (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate disease... |
DB00405 | DB00899 | 128 | 411 | [
"DDInter517",
"DDInter1579"
] | Dexbrompheniramine | Remifentanil | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Moderate | 1 | [
[
[
128,
24,
411
]
],
[
[
128,
24,
1322
],
[
1322,
40,
411
]
],
[
[
128,
24,
704
],
[
704,
1,
411
]
],
[
[
128,
24,
662
],
[
662,
24... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentani... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Remifentanil (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Remifent... |
DB00019 | DB09054 | 1,257 | 384 | [
"DDInter1405",
"DDInter905"
] | Pegfilgrastim | Idelalisib | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1257,
24,
384
]
],
[
[
1257,
24,
328
],
[
328,
24,
384
]
],
[
[
1257,
63,
491
],
[
491,
24,
384
]
],
[
[
1257,
24,
1619
],
[
1619,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Peginte... |
DB01601 | DB08871 | 833 | 36 | [
"DDInter1089",
"DDInter666"
] | Lopinavir | Eribulin | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to ... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
833,
24,
36
]
],
[
[
833,
63,
1674
],
[
1674,
24,
36
]
],
[
[
833,
24,
28
],
[
28,
63,
36
]
],
[
[
833,
24,
774
],
[
774,
24,
... | [
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
... | Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisac... |
DB00581 | DB09330 | 355 | 985 | [
"DDInter1018",
"DDInter1352"
] | Lactulose | Osimertinib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
355,
24,
985
]
],
[
[
355,
24,
657
],
[
657,
63,
985
]
],
[
[
355,
63,
1181
],
[
1181,
24,
985
]
],
[
[
355,
24,
28
],
[
28,
24,... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfen... |
DB00986 | DB09272 | 1,192 | 412 | [
"DDInter834",
"DDInter632"
] | Glycopyrronium | Eluxadoline | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1192,
24,
412
]
],
[
[
1192,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1192,
74,
1105
],
[
1105,
24,
412
]
],
[
[
1192,
24,
830
],
[
830,
... | [
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Glycopyrronium (Compound) resembles Trihexyphenidyl (Compound) and Glycopyrronium may cause a moderate inte... |
DB00099 | DB08889 | 440 | 350 | [
"DDInter735",
"DDInter299"
] | Filgrastim | Carfilzomib | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
440,
24,
350
]
],
[
[
440,
24,
1060
],
[
1060,
63,
350
]
],
[
[
440,
24,
482
],
[
482,
24,
350
]
],
[
[
440,
63,
1451
],
[
1451,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Tiog... |
DB00808 | DB01101 | 1,605 | 60 | [
"DDInter916",
"DDInter285"
] | Indapamide | Capecitabine | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
1605,
24,
60
]
],
[
[
1605,
21,
28906
],
[
28906,
60,
60
]
],
[
[
1605,
24,
286
],
[
286,
62,
60
]
],
[
[
1605,
40,
811
],
[
811,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Indapamide",
"{u} (Compound) causes {v} (Side Effect)",
"Gastroenteritis"
],
[
"Gastroenteritis",
"{u} (Side E... | Indapamide (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Capecitabine (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical e... |
DB00773 | DB08908 | 896 | 713 | [
"DDInter702",
"DDInter564"
] | Etoposide | Dimethyl fumarate | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
896,
24,
713
]
],
[
[
896,
24,
4
],
[
4,
24,
713
]
],
[
[
896,
63,
552
],
[
552,
24,
713
]
],
[
[
896,
24,
270
],
[
270,
63,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccin... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Etoposide may cause a moderate interaction that could exacerbate diseases wh... |
DB01080 | DB01246 | 855 | 820 | [
"DDInter1933",
"DDInter45"
] | Vigabatrin | Alimemazine | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
855,
24,
820
]
],
[
[
855,
63,
104
],
[
104,
40,
820
]
],
[
[
855,
63,
401
],
[
401,
24,
820
]
],
[
[
855,
24,
649
],
[
649,
1,
... | [
[
[
"Vigabatrin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Vigabatrin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Vigabatrin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Vigabatrin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction t... |
DB01136 | DB13142 | 772 | 841 | [
"DDInter305",
"DDInter274"
] | Carvedilol | Calcium glubionate anhydrous | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
772,
24,
841
]
],
[
[
772,
62,
1152
],
[
1152,
24,
841
]
],
[
[
772,
62,
1152
],
[
1152,
24,
1436
],
[
1436,
24,
841
]
],
[
[
772,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Carvedilol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronin... | Carvedilol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Carvedilol may cause a minor interaction that can limit clinical effects when taken with Lio... |
DB00279 | DB01132 | 1,152 | 1,130 | [
"DDInter1074",
"DDInter1472"
] | Liothyronine | Pioglitazone | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1152,
24,
1130
]
],
[
[
1152,
6,
15333
],
[
15333,
45,
1130
]
],
[
[
1152,
21,
28661
],
[
28661,
60,
1130
]
],
[
[
1152,
24,
890
],
[
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Liothyronine",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Com... | Liothyronine (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Pioglitazone (Compound)
Liothyronine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound)
Liothyronine may cause a moderate interaction that could exacerbate dise... |
DB00005 | DB05015 | 1,057 | 1,077 | [
"DDInter687",
"DDInter174"
] | Etanercept | Belinostat | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Major | 2 | [
[
[
1057,
25,
1077
]
],
[
[
1057,
25,
482
],
[
482,
24,
1077
]
],
[
[
1057,
24,
1136
],
[
1136,
63,
1077
]
],
[
[
1057,
24,
58
],
[
58,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belinostat"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} m... | Etanercept may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a ... |
DB00637 | DB00877 | 1,557 | 629 | [
"DDInter128",
"DDInter1678"
] | Astemizole | Sirolimus | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1557,
24,
629
]
],
[
[
1557,
6,
4973
],
[
4973,
45,
629
]
],
[
[
1557,
7,
18110
],
[
18110,
46,
629
]
],
[
[
1557,
7,
7669
],
[
7669,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Astemizole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Astemizole (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Sirolimus (Compound)
Astemizole (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Sirolimus (Compound)
Astemizole ... |
DB00545 | DB01285 | 751 | 708 | [
"DDInter1548",
"DDInter445"
] | Pyridostigmine | Corticotropin | Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of ... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
751,
24,
708
]
],
[
[
751,
24,
61
],
[
61,
24,
708
]
],
[
[
751,
40,
1372
],
[
1372,
63,
708
]
],
[
[
751,
24,
1011
],
[
1011,
6... | [
[
[
"Pyridostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Pyridostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
... | Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Pyridostigmine (Compound) resembles Neostigmine (Compound) and Neostigmine may cause a moderate interac... |
DB00722 | DB08882 | 743 | 1,281 | [
"DDInter1079",
"DDInter1070"
] | Lisinopril | Linagliptin | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
743,
24,
1281
]
],
[
[
743,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
743,
6,
4973
],
[
4973,
45,
1281
]
],
[
[
743,
21,
28966
],
[
28966,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Lisinopril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Linagliptin (Compound)
Lisinopril (Compound) causes Upper respiratory tract infection (Si... |
DB00196 | DB12245 | 600 | 823 | [
"DDInter743",
"DDInter1863"
] | Fluconazole | Triclabendazole | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
600,
24,
823
]
],
[
[
600,
23,
1247
],
[
1247,
23,
823
]
],
[
[
600,
24,
1612
],
[
1612,
24,
823
]
],
[
[
600,
35,
1622
],
[
1622,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fostem... |
DB00726 | DB06603 | 1,164 | 39 | [
"DDInter1876",
"DDInter1387"
] | Trimipramine | Panobinostat | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1164,
25,
39
]
],
[
[
1164,
23,
112
],
[
112,
23,
39
]
],
[
[
1164,
24,
272
],
[
272,
24,
39
]
],
[
[
1164,
1,
1335
],
[
1335,
2... | [
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Trimipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniram... |
DB00832 | DB01069 | 499 | 401 | [
"DDInter1446",
"DDInter1533"
] | Phensuximide | Promethazine | Phensuximide is a member of the succinimide class with anticonvulsant properties. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
499,
24,
401
]
],
[
[
499,
24,
1264
],
[
1264,
63,
401
]
],
[
[
499,
1,
759
],
[
759,
24,
401
]
],
[
[
499,
1,
341
],
[
341,
63,... | [
[
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[... | Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Phensuximide (Compound) resembles Primidone (Compound) and Primidone may cause a moderate interaction that could e... |
DB00530 | DB12825 | 1,195 | 1,375 | [
"DDInter667",
"DDInter1032"
] | Erlotinib | Lefamulin | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1195,
24,
1375
]
],
[
[
1195,
24,
159
],
[
159,
63,
1375
]
],
[
[
1195,
63,
1101
],
[
1101,
24,
1375
]
],
[
[
1195,
24,
98
],
[
98,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bex... |
DB00557 | DB08875 | 252 | 1,618 | [
"DDInter895",
"DDInter262"
] | Hydroxyzine | Cabozantinib | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
252,
25,
1618
]
],
[
[
252,
23,
112
],
[
112,
23,
1618
]
],
[
[
252,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
252,
24,
480
],
[
480,
... | [
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric ac... |
DB00655 | DB06404 | 559 | 1,514 | [
"DDInter682",
"DDInter869"
] | Estrone | Human C1-esterase inhibitor | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and... | Moderate | 1 | [
[
[
559,
24,
1514
]
],
[
[
559,
1,
1581
],
[
1581,
24,
1514
]
],
[
[
559,
40,
1438
],
[
1438,
24,
1514
]
],
[
[
559,
25,
350
],
[
350,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Testolactone"
],
[
"Testolactone",
"{u} may ... | Estrone (Compound) resembles Testolactone (Compound) and Testolactone may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor
Estrone (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00039 | DB00188 | 1,253 | 168 | [
"DDInter1380",
"DDInter222"
] | Palifermin | Bortezomib | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Moderate | 1 | [
[
[
1253,
24,
168
]
],
[
[
1253,
24,
1307
],
[
1307,
62,
168
]
],
[
[
1253,
24,
1362
],
[
1362,
63,
168
]
],
[
[
1253,
24,
599
],
[
599,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may... |
DB00086 | DB01088 | 1,167 | 714 | [
"DDInter1712",
"DDInter908"
] | Streptokinase | Iloprost | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1167,
24,
714
]
],
[
[
1167,
23,
539
],
[
539,
62,
714
]
],
[
[
1167,
24,
1638
],
[
1638,
24,
714
]
],
[
[
1167,
64,
1432
],
[
1432,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
... | Streptokinase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Iloprost
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandola... |
DB00330 | DB06317 | 238 | 1,626 | [
"DDInter689",
"DDInter630"
] | Ethambutol | Elotuzumab | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
238,
24,
1626
]
],
[
[
238,
24,
973
],
[
973,
24,
1626
]
],
[
[
238,
24,
310
],
[
310,
63,
1626
]
],
[
[
238,
63,
367
],
[
367,
... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabaz... |
DB00816 | DB09564 | 1,674 | 1,296 | [
"DDInter1346",
"DDInter930"
] | Orciprenaline | Insulin degludec | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1674,
24,
1296
]
],
[
[
1674,
75,
17
],
[
17,
24,
1296
]
],
[
[
1674,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1674,
63,
1645
],
[
1645,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Orciprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with... | Orciprenaline (Compound) resembles Sotalol (Compound) and Orciprenaline may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Orciprenaline may cause a moderate interaction that could exacerba... |
DB00439 | DB01110 | 289 | 86 | [
"DDInter341",
"DDInter1209"
] | Cerivastatin | Miconazole | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
289,
24,
86
]
],
[
[
289,
24,
466
],
[
466,
62,
86
]
],
[
[
289,
24,
1593
],
[
1593,
63,
86
]
],
[
[
289,
24,
147
],
[
147,
24,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Miconazole
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and ... |
DB09065 | DB11791 | 760 | 785 | [
"DDInter424",
"DDInter287"
] | Cobicistat | Capmatinib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Major | 2 | [
[
[
760,
25,
785
]
],
[
[
760,
64,
1135
],
[
1135,
23,
785
]
],
[
[
760,
63,
868
],
[
868,
24,
785
]
],
[
[
760,
64,
866
],
[
866,
2... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Cobicistat may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a ... |
DB00867 | DB01611 | 1,052 | 1,487 | [
"DDInter1606",
"DDInter893"
] | Ritodrine | Hydroxychloroquine | Adrenergic beta-agonist used to control premature labor. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1052,
24,
1487
]
],
[
[
1052,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
1052,
63,
245
],
[
245,
24,
1487
]
],
[
[
1052,
24,
473
],
[
473,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride ma... |
DB00434 | DB09117 | 13 | 957 | [
"DDInter459",
"DDInter1391"
] | Cyproheptadine | Paraldehyde | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. ... | Moderate | 1 | [
[
[
13,
24,
957
]
],
[
[
13,
24,
1264
],
[
1264,
24,
957
]
],
[
[
13,
63,
1233
],
[
1233,
24,
957
]
],
[
[
13,
24,
1609
],
[
1609,
6... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and T... |
DB00960 | DB06792 | 887 | 1,606 | [
"DDInter1471",
"DDInter1023"
] | Pindolol | Lanthanum carbonate | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
887,
24,
1606
]
],
[
[
887,
1,
88
],
[
88,
24,
1606
]
],
[
[
887,
62,
1152
],
[
1152,
24,
1606
]
],
[
[
887,
40,
1121
],
[
1121,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a mo... | Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Pindolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction tha... |
DB01284 | DB04574 | 1,042 | 177 | [
"DDInter1782",
"DDInter684"
] | Tetracosactide | Estrone sulfate (topical) | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane. | Moderate | 1 | [
[
[
1042,
24,
177
]
],
[
[
1042,
63,
380
],
[
380,
1,
177
]
],
[
[
1042,
24,
35
],
[
35,
1,
177
]
],
[
[
1042,
63,
380
],
[
380,
1,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone sulfate"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated est... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estrone sulfate (Compound)
Tetracosactide may c... |
DB00381 | DB00673 | 376 | 723 | [
"DDInter79",
"DDInter112"
] | Amlodipine | Aprepitant | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
376,
24,
723
]
],
[
[
376,
6,
7950
],
[
7950,
45,
723
]
],
[
[
376,
21,
28642
],
[
28642,
60,
723
]
],
[
[
376,
63,
1101
],
[
1101,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Amlodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Amlodipine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Amlodipine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Aprepitant (Compound)
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene m... |
DB00307 | DB08815 | 1,101 | 154 | [
"DDInter202",
"DDInter1104"
] | Bexarotene | Lurasidone | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1101,
24,
154
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
154
]
],
[
[
1101,
21,
28963
],
[
28963,
60,
154
]
],
[
[
1101,
24,
1033
],
[
1033... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Bexarotene (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Lurasidone (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib... |
DB00081 | DB00087 | 273 | 599 | [
"DDInter1838",
"DDInter41"
] | Tositumomab | Alemtuzumab | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Moderate | 1 | [
[
[
273,
24,
599
]
],
[
[
273,
24,
597
],
[
597,
63,
599
]
],
[
[
273,
25,
291
],
[
291,
63,
599
]
],
[
[
273,
63,
1184
],
[
1184,
2... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Tositumomab may lead to a major life threatening interaction when taken with Argatroban and Argatrob... |
DB06788 | DB09564 | 1,616 | 1,296 | [
"DDInter864",
"DDInter930"
] | Histrelin | Insulin degludec | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1616,
24,
1296
]
],
[
[
1616,
64,
17
],
[
17,
24,
1296
]
],
[
[
1616,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
1616,
24,
659
],
[
659,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",... | Histrelin may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause ... |
DB01227 | DB01501 | 1,301 | 1,118 | [
"DDInter1043",
"DDInter549"
] | Levacetylmethadol | Difenoxin | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | Moderate | 1 | [
[
[
1301,
24,
1118
]
],
[
[
1301,
40,
11264
],
[
11264,
40,
1118
]
],
[
[
1301,
40,
576
],
[
576,
1,
1118
]
],
[
[
1301,
74,
1688
],
[
168... | [
[
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compo... | Levacetylmethadol (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Difenoxin (Compound)
Levacetylmethadol (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Difenoxin (Compound)
Levacetylmethadol (Compound) resembles Diphenoxylate (Compound) and Levacetylmethadol ... |
DB00609 | DB06186 | 595 | 1,439 | [
"DDInter694",
"DDInter969"
] | Ethionamide | Ipilimumab | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
595,
24,
1439
]
],
[
[
595,
63,
912
],
[
912,
24,
1439
]
],
[
[
595,
24,
267
],
[
267,
24,
1439
]
],
[
[
595,
24,
310
],
[
310,
... | [
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
]... | Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Nal... |
DB09065 | DB11995 | 760 | 1,634 | [
"DDInter424",
"DDInter143"
] | Cobicistat | Avatrombopag | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Moderate | 1 | [
[
[
760,
24,
1634
]
],
[
[
760,
63,
1622
],
[
1622,
24,
1634
]
],
[
[
760,
64,
759
],
[
759,
24,
1634
]
],
[
[
760,
25,
913
],
[
913,
... | [
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Cobicistat may lead to a major life threatening interaction when taken with Primidone and Primidone may ca... |
DB00158 | DB00384 | 356 | 1,275 | [
"DDInter771",
"DDInter1859"
] | Folic acid | Triamterene | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Moderate | 1 | [
[
[
356,
24,
1275
]
],
[
[
356,
24,
706
],
[
706,
40,
1275
]
],
[
[
356,
21,
28722
],
[
28722,
60,
1275
]
],
[
[
356,
24,
706
],
[
706,
... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamterene"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lamotrigine"
],
[
... | Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Lamotrigine and Lamotrigine (Compound) resembles Triamterene (Compound)
Folic acid (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Triamterene (Compound)
Folic acid may cause a moderate interaction th... |
DB00550 | DB00704 | 99 | 267 | [
"DDInter1541",
"DDInter1263"
] | Propylthiouracil | Naltrexone | A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
99,
24,
267
]
],
[
[
99,
18,
2183
],
[
2183,
57,
267
]
],
[
[
99,
21,
28787
],
[
28787,
60,
267
]
],
[
[
99,
24,
850
],
[
850,
6... | [
[
[
"Propylthiouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Propylthiouracil",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downreg... | Propylthiouracil (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Naltrexone (Compound)
Propylthiouracil (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Naltrexone (Compound)
Propylthiouracil may cause a moderate interaction that could exacerbate diseases w... |
DB00951 | DB08889 | 1,072 | 350 | [
"DDInter986",
"DDInter299"
] | Isoniazid | Carfilzomib | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
1072,
24,
350
]
],
[
[
1072,
21,
28745
],
[
28745,
60,
350
]
],
[
[
1072,
63,
482
],
[
482,
24,
350
]
],
[
[
1072,
24,
310
],
[
310,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Isoniazid",
"{u} (Compound) causes {v} (Side Effect)",
"Neuropathy peripheral"
],
[
"Neuropathy peripheral",
"{u... | Isoniazid (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Carfilzomib (Compound)
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases ... |
DB00962 | DB12010 | 1,639 | 214 | [
"DDInter1957",
"DDInter785"
] | Zaleplon | Fostamatinib | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1639,
24,
214
]
],
[
[
1639,
62,
1324
],
[
1324,
24,
214
]
],
[
[
1639,
24,
222
],
[
222,
24,
214
]
],
[
[
1639,
24,
1017
],
[
1017,
... | [
[
[
"Zaleplon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Zaleplon",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troglitazone"
],
[
... | Zaleplon may cause a minor interaction that can limit clinical effects when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibut... |
DB08930 | DB11093 | 1,459 | 636 | [
"DDInter582",
"DDInter273"
] | Dolutegravir | Calcium citrate | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Major | 2 | [
[
[
1459,
25,
636
]
],
[
[
1459,
64,
115
],
[
115,
25,
636
]
],
[
[
1459,
21,
28762
],
[
28762,
60,
819
],
[
819,
24,
636
]
],
[
[
1459,
... | [
[
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcium citrate"
]
],
[
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum... | Dolutegravir may lead to a major life threatening interaction when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Calcium citrate
Dolutegravir (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Acebutolol (Compound) and... |
DB00108 | DB12159 | 1,066 | 12 | [
"DDInter1268",
"DDInter609"
] | Natalizumab | Dupilumab | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that indu... | Major | 2 | [
[
[
1066,
25,
12
]
],
[
[
1066,
23,
1461
],
[
1461,
23,
12
]
],
[
[
1066,
64,
599
],
[
599,
24,
12
]
],
[
[
1066,
24,
1136
],
[
1136,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dupilumab
Natalizumab may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a m... |
DB00526 | DB14730 | 1,555 | 1,412 | [
"DDInter1355",
"DDInter264"
] | Oxaliplatin | Calaspargase pegol | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1555,
24,
1412
]
],
[
[
1555,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
1555,
63,
322
],
[
322,
24,
1412
]
],
[
[
1555,
25,
868
],
[
868,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin ... |
DB00722 | DB14018 | 743 | 431 | [
"DDInter1079",
"DDInter244"
] | Lisinopril | Bromotheophylline | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a ... | Moderate | 1 | [
[
[
743,
24,
431
]
],
[
[
743,
1,
1058
],
[
1058,
24,
431
]
],
[
[
743,
63,
1061
],
[
1061,
24,
431
]
],
[
[
743,
40,
1638
],
[
1638,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromotheophylline"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a mo... | Lisinopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Bromotheophylline
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction t... |
DB00333 | DB09472 | 576 | 1,383 | [
"DDInter1166",
"DDInter1693"
] | Methadone | Sodium sulfate | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Major | 2 | [
[
[
576,
25,
1383
]
],
[
[
576,
25,
609
],
[
609,
24,
1383
]
],
[
[
576,
1,
146
],
[
146,
24,
1383
]
],
[
[
576,
24,
1311
],
[
1311,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
... | Methadone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Methadone (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interaction that could ... |
DB00794 | DB11691 | 759 | 1,499 | [
"DDInter1521",
"DDInter1258"
] | Primidone | Naldemedine | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Major | 2 | [
[
[
759,
25,
1499
]
],
[
[
759,
63,
723
],
[
723,
24,
1499
]
],
[
[
759,
64,
1419
],
[
1419,
24,
1499
]
],
[
[
759,
25,
1670
],
[
1670,
... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant"... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Primidone may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a mod... |
DB00445 | DB01142 | 322 | 1,264 | [
"DDInter655",
"DDInter593"
] | Epirubicin | Doxepin | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
322,
24,
1264
]
],
[
[
322,
63,
508
],
[
508,
24,
1264
]
],
[
[
322,
24,
401
],
[
401,
24,
1264
]
],
[
[
322,
7,
6952
],
[
6952,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethaz... |
DB00024 | DB00046 | 818 | 1,179 | [
"DDInter1800",
"DDInter940"
] | Thyrotropin alfa | Insulin lispro | Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cance... | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Moderate | 1 | [
[
[
818,
24,
1179
]
],
[
[
818,
24,
1645
],
[
1645,
63,
1179
]
],
[
[
818,
24,
1645
],
[
1645,
62,
333
],
[
333,
62,
1179
]
],
[
[
818,
... | [
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
... | Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Metform... |
DB01246 | DB09128 | 820 | 1,241 | [
"DDInter45",
"DDInter231"
] | Alimemazine | Brexpiprazole | A phenothiazine derivative that is used as an antipruritic. | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
820,
24,
1241
]
],
[
[
820,
24,
549
],
[
549,
24,
1241
]
],
[
[
820,
63,
1647
],
[
1647,
24,
1241
]
],
[
[
820,
24,
1296
],
[
1296,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose a... |
DB00731 | DB08815 | 1,144 | 154 | [
"DDInter1269",
"DDInter1104"
] | Nateglinide | Lurasidone | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1144,
24,
154
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
154
]
],
[
[
1144,
21,
29402
],
[
29402,
60,
154
]
],
[
[
1144,
24,
1033
],
[
1033... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Nateglinide (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when tak... |
DB00976 | DB09073 | 1,056 | 951 | [
"DDInter1758",
"DDInter1379"
] | Telithromycin | Palbociclib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Major | 2 | [
[
[
1056,
25,
951
]
],
[
[
1056,
25,
1476
],
[
1476,
63,
951
]
],
[
[
1056,
24,
710
],
[
710,
63,
951
]
],
[
[
1056,
64,
467
],
[
467,
... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
... | Telithromycin may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib m... |
DB00773 | DB00834 | 896 | 932 | [
"DDInter702",
"DDInter1215"
] | Etoposide | Mifepristone | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
896,
24,
932
]
],
[
[
896,
6,
7524
],
[
7524,
45,
932
]
],
[
[
896,
7,
7669
],
[
7669,
46,
932
]
],
[
[
896,
18,
10699
],
[
10699,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",... | Etoposide (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Mifepristone (Compound)
Etoposide (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Mifepristone (Compound)
Etoposide (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Mifepristone (Compound)
Etoposide... |
DB00701 | DB00860 | 1,091 | 891 | [
"DDInter90",
"DDInter1513"
] | Amprenavir | Prednisolone | Amprenavir is a protease inhibitor used to treat HIV infection. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1091,
24,
891
]
],
[
[
1091,
63,
1351
],
[
1351,
40,
891
]
],
[
[
1091,
64,
175
],
[
175,
40,
891
]
],
[
[
1091,
24,
167
],
[
167,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flunisolide"
],
[... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Prednisolone (Compound)
Amprenavir may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Amp... |
DB01101 | DB09074 | 60 | 1,362 | [
"DDInter285",
"DDInter1327"
] | Capecitabine | Olaparib | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
60,
24,
1362
]
],
[
[
60,
63,
896
],
[
896,
24,
1362
]
],
[
[
60,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
60,
24,
385
],
[
385,
63... | [
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustek... |
DB00331 | DB01211 | 1,645 | 609 | [
"DDInter1164",
"DDInter393"
] | Metformin | Clarithromycin | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1645,
24,
609
]
],
[
[
1645,
18,
20003
],
[
20003,
57,
609
]
],
[
[
1645,
21,
28759
],
[
28759,
60,
609
]
],
[
[
1645,
24,
222
],
[
22... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Metformin",
"{u} (Compound) downregulates {v} (Gene)",
"NOSIP"
],
[
"NOSIP",
"{u} (Gene) is downregulated by ... | Metformin (Compound) downregulates NOSIP (Gene) and NOSIP (Gene) is downregulated by Clarithromycin (Compound)
Metformin (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Clarithromycin (Compound)
Metformin may cause a moderate interaction that could ex... |
DB00694 | DB08820 | 51 | 1,478 | [
"DDInter485",
"DDInter997"
] | Daunorubicin | Ivacaftor | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
51,
24,
1478
]
],
[
[
51,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
51,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
51,
25,
318
],
[
318,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Daunorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Daunorubicin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Daunorubicin may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram ma... |
DB01234 | DB09039 | 1,220 | 1,670 | [
"DDInter513",
"DDInter629"
] | Dexamethasone | Eliglustat | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1220,
24,
1670
]
],
[
[
1220,
63,
479
],
[
479,
23,
1670
]
],
[
[
1220,
24,
1135
],
[
1135,
62,
1670
]
],
[
[
1220,
24,
1409
],
[
1409... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Nalox... |
DB00792 | DB01041 | 832 | 770 | [
"DDInter1878",
"DDInter1789"
] | Tripelennamine | Thalidomide | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
832,
24,
770
]
],
[
[
832,
24,
849
],
[
849,
63,
770
]
],
[
[
832,
63,
1533
],
[
1533,
24,
770
]
],
[
[
832,
40,
649
],
[
649,
6... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone a... |
DB00295 | DB00880 | 475 | 359 | [
"DDInter1244",
"DDInter360"
] | Morphine | Chlorothiazide | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
475,
24,
359
]
],
[
[
475,
24,
1577
],
[
1577,
1,
359
]
],
[
[
475,
21,
28784
],
[
28784,
60,
359
]
],
[
[
475,
24,
1123
],
[
1123,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
],
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Morphine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Chlorothiazide (Compound)
Morphine m... |
DB00364 | DB01320 | 417 | 651 | [
"DDInter1717",
"DDInter783"
] | Sucralfate | Fosphenytoin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
417,
24,
651
]
],
[
[
417,
63,
362
],
[
362,
1,
651
]
],
[
[
417,
6,
1829
],
[
1829,
45,
651
]
],
[
[
417,
21,
28882
],
[
28882,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Sucralfate (Compound) binds ALB (Gene) and ALB (Gene) is bound by Fosphenytoin (Compound)
Sucralfate (Compound) causes Body temperature increased (Side Effect) ... |
DB00557 | DB01142 | 252 | 1,264 | [
"DDInter895",
"DDInter593"
] | Hydroxyzine | Doxepin | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
252,
24,
1264
]
],
[
[
252,
24,
401
],
[
401,
24,
1264
]
],
[
[
252,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
252,
40,
11296
],
[
11296,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Dox... |
DB00704 | DB15066 | 267 | 445 | [
"DDInter1263",
"DDInter821"
] | Naltrexone | Givosiran | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
267,
24,
445
]
],
[
[
267,
63,
1555
],
[
1555,
24,
445
]
],
[
[
267,
24,
850
],
[
850,
24,
445
]
],
[
[
267,
25,
1377
],
[
1377,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin ... |
DB12015 | DB12825 | 1,033 | 1,375 | [
"DDInter53",
"DDInter1032"
] | Alpelisib | Lefamulin | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolis... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1033,
24,
1375
]
],
[
[
1033,
24,
159
],
[
159,
63,
1375
]
],
[
[
1033,
63,
1532
],
[
1532,
24,
1375
]
],
[
[
1033,
24,
1476
],
[
1476... | [
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifo... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.